Financial Report: Lilly 3Q11

Lilly 3Q11

3Q Revenues: $6.1 billion (+9%)

3Q Earnings: $1.2 billion (-5%)

YTD Revenues: $18.2 billion (+8%)

YTD Earnings: $3.5 billion (-11%)

Comments: Cymbalta sales were up 29% to $1.1 billion in the quarter. Humalog sales were up 20% to $593.2 million. Forteo and Strattera sales were also up 20% to $240.3 million and $153.2 million, respectively. Cialis sales were up 16% to $469.8 million. Alimta sales were up 12% to $629.7 million. Gemzar sales dropped 72% to $91.0 million due to generic competition. U.S. revenues increased 4% to $3.3 billion. Revenue outside the U.S. increased 15% to $2.9 billion due to the positive impact of foreign exchange and increased volume.